Specialty biopharmaceutical company EyePoint Pharmaceuticals reported $2 million in revenue for the first quarter of 2019, up from $928,000 year over year.
Three details from the financial report:
1. EyePoint's cash and cash equivalents totaled $43.4 million at the end of the third quarter.
2. Operating expenses for the third quarter increased to $16.7 million from $5.6 million the prior year.
3. The company reported a third-quarter net loss of $19.2 million, or $0.20 per share, compared to a net loss of $7 million, or $0.15 per share, for the prior-year quarter.